Learning curves in radiological reporting of whole-body MRI in plasma cell disease: a retrospective study.
Durie–Salmon PLUS
Inter-observer agreement
Learning curves
Plasma cell disease
Whole-body MRI
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
16
04
2020
accepted:
25
06
2021
pubmed:
27
7
2021
medline:
19
11
2021
entrez:
26
7
2021
Statut:
ppublish
Résumé
The plasma cell disease is been studying by the whole-body MRI technology. However, the time requested to learn this radiological technique is unknown. To esteem, quantitatively and qualitatively, the essential time to learn the whole-body MRI diffusion-weighted imaging with background body signal suppression in patients with plasma cell disease. Between January 2015 and February 2017, three readers in-training with different levels of experience examined the anonymised and randomised whole-body MRI images of 52 patients with a diagnosis of plasma cell disease and analysed their morphological (T1w, T2w with and without fat suppression) and functional sequences. Reports of an expert radiologist were considered the standard of reference. Images were analysed in two sessions, during which each reader was timed. Readers reported the number of segments with lesions and staged the disease using the Durie-Salmon PLUS staging system. Weighted Cohen's ĸ and Z-test were used to compare the trainees' reports with those of the expert radiologist, and learning curves were drawn up to show changes between the two sessions. Weighted Cohen's ĸ of number of lesioned segments increased from 0.536 ± 0.123 to 0.831 ± 0.129 (Prob > Z under 0.005), thus approaching the goal of ĸ > 0.8. Trainees reached the level of experienced radiologist in terms of time by the 33rd patient. Agreement concerning the Durie-Salmon PLUS increased from 0.536 ± 0.123 to 0.831 ± 0.129 (Prob > Z under 0.005). The findings of this study demonstrate that whole-body MRI with DWIBS can be learned in about 80 reports and leads to a high level of inter-observer concordance when using the Durie-Salmon PLUS staging system.
Sections du résumé
BACKGROUND
BACKGROUND
The plasma cell disease is been studying by the whole-body MRI technology. However, the time requested to learn this radiological technique is unknown.
PURPOSE
OBJECTIVE
To esteem, quantitatively and qualitatively, the essential time to learn the whole-body MRI diffusion-weighted imaging with background body signal suppression in patients with plasma cell disease.
MATERIALS AND METHODS
METHODS
Between January 2015 and February 2017, three readers in-training with different levels of experience examined the anonymised and randomised whole-body MRI images of 52 patients with a diagnosis of plasma cell disease and analysed their morphological (T1w, T2w with and without fat suppression) and functional sequences. Reports of an expert radiologist were considered the standard of reference. Images were analysed in two sessions, during which each reader was timed. Readers reported the number of segments with lesions and staged the disease using the Durie-Salmon PLUS staging system. Weighted Cohen's ĸ and Z-test were used to compare the trainees' reports with those of the expert radiologist, and learning curves were drawn up to show changes between the two sessions.
RESULTS
RESULTS
Weighted Cohen's ĸ of number of lesioned segments increased from 0.536 ± 0.123 to 0.831 ± 0.129 (Prob > Z under 0.005), thus approaching the goal of ĸ > 0.8. Trainees reached the level of experienced radiologist in terms of time by the 33rd patient. Agreement concerning the Durie-Salmon PLUS increased from 0.536 ± 0.123 to 0.831 ± 0.129 (Prob > Z under 0.005).
CONCLUSIONS
CONCLUSIONS
The findings of this study demonstrate that whole-body MRI with DWIBS can be learned in about 80 reports and leads to a high level of inter-observer concordance when using the Durie-Salmon PLUS staging system.
Identifiants
pubmed: 34309766
doi: 10.1007/s11547-021-01391-3
pii: 10.1007/s11547-021-01391-3
pmc: PMC8558285
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1451-1459Informations de copyright
© 2021. The Author(s).
Références
AJR Am J Roentgenol. 1993 May;160(5):1049-52
pubmed: 8470574
Clin Radiol. 2019 Apr;74(4):327.e7-327.e19
pubmed: 30732923
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
AJR Am J Roentgenol. 1994 Jan;162(1):215-21
pubmed: 8273669
Br J Haematol. 2012 Dec;159(5):499-513
pubmed: 22881361
Ann Hematol. 2009 May;88(5):457-64
pubmed: 18941746
J Clin Oncol. 2010 Mar 20;28(9):1606-10
pubmed: 20177023
World J Orthop. 2014 Jul 18;5(3):272-82
pubmed: 25035830
Leuk Lymphoma. 2018 Nov;59(11):2546-2556
pubmed: 29431555
Br J Haematol. 2013 Jul;162(1):50-61
pubmed: 23617231
Radiol Bras. 2017 May-Jun;50(3):162-169
pubmed: 28670027
Acad Radiol. 2015 Oct;22(10):1236-41
pubmed: 26254544
Eur J Cancer. 2006 Jul;42(11):1539-43
pubmed: 16777405
Brachytherapy. 2016 Jul-Aug;15(4):426-434
pubmed: 27220699
BJU Int. 2016 Jan;117(1):80-6
pubmed: 25099182
Radiology. 2004 Apr;231(1):11-23
pubmed: 14990813
Rofo. 2007 Jul;179(7):721-7
pubmed: 17592809
Radiol Med. 2018 May;123(5):359-366
pubmed: 29292479
Radiology. 1998 Dec;209(3):653-60
pubmed: 9844655
Br J Haematol. 1999 Jul;106(1):35-9
pubmed: 10444160
Prim Care. 2016 Dec;43(4):677-691
pubmed: 27866585
Br J Haematol. 2009 Jan;144(1):86-94
pubmed: 19016727
Eur Radiol. 2006 May;16(5):1005-14
pubmed: 16463030
J Digit Imaging. 2008 Oct;21 Suppl 1:S50-8
pubmed: 18266034
MAGMA. 2019 Sep;32(Suppl 1):107-233
pubmed: 31552517
Radiology. 2009 Aug;252(2):477-85
pubmed: 19703885